MorphoSys Reports Filing for Phase 1b/2a Trial for its Lead Program MOR103 in Rheumatoid Arthritis

News   Jun 30, 2009

 
MorphoSys Reports Filing for Phase 1b/2a Trial for its Lead Program MOR103 in Rheumatoid Arthritis
 
 
 

RELATED ARTICLES

Protein's Role in Mitochondrial Metabolism Identified

News

EXD2, a protein previously thought to be localised to the nucleus, has a key role in the production of proteins by mitochondria.

READ MORE

PPD and Quotient Sciences Form Innovative Partnership to Accelerate Pediatric Drug Development

News

Will shorten timelines, reduce costs and simplify contracting process in pediatric programs.

READ MORE

Proteasome Blocker Brings Glaucoma Gene Therapy Closer

News

An enhanced gene therapy technique that pairs a viral vector with a proteasome blockade has doubled the therapy's efficiency.

READ MORE

 

Comments | 0 ADD COMMENT

Like what you just read? You can find similar content on the communities below.

Proteomics & Metabolomics

To personalize the content you see on Technology Networks homepage, Log In or Subscribe for Free

LOGIN SUBSCRIBE FOR FREE